SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bob L who wrote (376)11/20/1999 2:24:00 PM
From: Vector1  Read Replies (1) of 666
 
Bob,
IDPh can not use dosemitry in administering Y2B8 and as a result the therapeudic dose is based upon body weight and is not as precise leading to the potential for either to large or to small a dose. IMO, although it is admitedly dificult to compare studies it looks like Bex has a better side effect profile than Y2B8. One possible reason is that the gamma radiation emitted by Y tends to accumulate in the bone.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News